Specifically, the use of drug-containing cubosomes engineered to target CD44+ tumor cells did succeed therapeutically in several cancer cell lines in vitro [41], with continuing research to evaluate the use of CD44 as a therapeutic target [42]. This evidence concerns the gene CD44 and neoplasm.